With clinical data showing clear signals of efficacy of PROTACs, increasing number of candidates accelerated towards clinical development and the rise of molecular glues unlike ever seen before, 2020 certainly was a promising year for the field of targeted protein degradation.  

In the context of rapid progress and mounting desire to transform degrader tools into transformative therapies, the 4th Annual Targeted Protein Degradation (TPD) Summit will reunite large pharma, innovative biotechs and pioneering academics to discuss the full and comprehensive range of next generation protein degrading technologies to achieve efficient degradation of a broad range of disease-causing targets.  

From optimizing PKPD, to overcoming innate and acquired resistance and enabling brain barrier penetration, the 4th Annual TPD Summit will be your most comprehensive guide to addressing the most unique challenges of next generation targeted protein degraders to power your strategies and pipelines towards achieving your 2021/2022 milestones.